Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review

Cover Page

Cite item

Full Text

Abstract

The article discusses modern approaches to screening for dyslipidemia and its control, target levels of low-density lipoproteins (LDL), initiation of lipid-lowering therapy depending on the total risk on the Systematic Coronary Risk Evaluation (SCORE) scale, considering the effects of age, gender, smoking, blood pressure, lipid levels, which are of crucial importance for selecting preventive and therapeutic strategies in patients with several risk factors. Different types of therapy for dyslipidemia are discussed as of monotherapy with statins and, in combination with ezetimibe, inhibitors of the enzyme proprotein convertase subtilisin-kexin type 9 (PCSK9). New lipid-lowering drugs are highlighted: bempedoic acid and inclisiran, a synthetic small interfering RNA (siRNA) conjugated with a hydrocarbon of three-antennary N-acetylgalactosamine, which activates the natural RNA interference mechanism to cleave the mRNA of the PCSK9 enzyme and prevent its translation into a protein molecule. This increases the number of receptors for LDL and reducing their amount in the blood. We present our results of assessing the use of lipid-lowering therapy and achievement of the target LDL value in very high-risk patients. Innovative biotechnological drugs based on human monoclonal antibodies or antisense oligonucleodins create additional opportunities for improving the treatment of statin-resistant forms of dyslipidemia in patients with a very high cardiovascular risk. The article aims to increase the level of knowledge about modern approaches to lipid-lowering therapy of general practitioners, cardiologists of the primary care settings and will be of interest to other specialists.

About the authors

Vera N. Larina

Pirogov Russian National Research Medical University

Email: larinav@mail.ru
ORCID iD: 0000-0001-7825-5597
SPIN-code: 3674-9620

MD, D. Sci. (Med.), Prof., department head

Russian Federation, 1, Ostrovityanova, Moscow, 117997

Milada G. Golovko

Pirogov Russian National Research Medical University

Email: miladagolovko@yandex.ru
ORCID iD: 0000-0003-2196-6739
SPIN-code: 2329-0384

MD, Cand. Sci. (Med.), Associate Prof.

Russian Federation, 1, Ostrovityanova, Moscow, 117997

Vladimir G. Larin

Pirogov Russian National Research Medical University

Email: larinvladimir@mail.ru
ORCID iD: 0000-0002-3177-3407
SPIN-code: 9394-2871

MD, Cand. Sci. (Med.), Associate Prof.

Russian Federation, 1, Ostrovityanova, Moscow, 117997

Tatyana N. Mironovna

Pirogov Russian National Research Medical University

Email: mironova.tanya.90@yandex.ru
ORCID iD: 0000-0002-6430-7111
SPIN-code: 1089-3342

MD, Cand. Sci. (Med.), department assistant

Russian Federation, 1, Ostrovityanova, Moscow, 117997

Denis A. Orlov

Pirogov Russian National Research Medical University

Author for correspondence.
Email: rakdos@narod.ru
ORCID iD: 0000-0002-0994-8880
SPIN-code: 3867-5378

MD, Cand. Sci. (Med.), department assistant

Russian Federation, 1, Ostrovityanova, Moscow, 117997

References

  1. Boytsov SA, Demkina AE, Oshchepkova EV, Dolgusheva YuA. Progress and Problems of Practical Cardiology in Russia at the Present Stage. Kardiologiia. 2019;59(3):53–59. (In Russ). doi: 10.18087/cardio.2019.3.10242
  2. Bubnova MG, Parnes LE. Modern principles of atherogenic dyslipidemia management in special groups of patients. Cardiosomatics. 2020;11(1): 6–16. (In Russ). doi: 10.26442/22217185.2020.1.200089
  3. Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision. Journal of Atherosclerosis and Dyslipidemias. 2020;1(38):7–42. (In Russ). doi: 10.34687/2219-8202.JAD.2020.01.0002
  4. Tsaban G. Low-density lipoprotein cholesterol and cardiovascular risk: a necessary causal agent but an insufficient predictor. Eur J Prev Cardiol. 2022;29(3):125–127. doi: 10.1093/eurjpc/zwab098
  5. Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Eurasian Association of Cardiology (EAC) / Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian Heart Journal. 2020;2:6–29. (In Russ). doi: 10.38109/2225-1685-2020-2-6-29
  6. Mach F, Baigent C, Catapano AL, et al. 2019 ESC / EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi: 10.1093/eurheartj/ehz455
  7. Kukharchuk VV. About the new version of recommendations for the correction of dyslipidemia for the prevention of atherosclerosis and its complications. Journal of Atherosclerosis and Dyslipidemias. 2020;1(38):5–6. (In Russ). doi: 10.34687/2219-8202.JAD.2020.01.0001
  8. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ). doi: 10.15829/1728-8800-2022-3235
  9. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484
  10. Sergienko IV, Shestakova MV, Boitsov SA, et al. Extreme risk category in the stratification of cardiovascular complications. Consensus Council of experts. Farmateka. 2019;26(4):138–143. (In Russ). doi: 10.18565/pharmateca.2019.4.138-143
  11. Ezhov MV, Matveeva MA, Alekseeva IA. Rosuvastatin + ezetimibe: possibilities of usage in a novel coronavirus infection era. Journal of Atherosclerosis and Dyslipidemias. 2021;3(44):14–25. (In Russ). doi: 10.34687/2219–8202.JAD.2021.03.0002
  12. Sivkov AS, Shih EV, Osadchuk MA, et al. Complex assessment of efficacy of statins prescribed at most by clinicians. Cardiovascular Therapy and Prevention. 2018;17(3):22–26. (In Russ.) doi: 10.15829/1728-8800-2018-3-22-26
  13. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Study (4S). Lancet. 1994;344(8934):1383–1389.
  14. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5
  15. Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipidlowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes: from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54(25):2358–2362. doi: 10.1016/j.jacc.2009.10.005
  16. Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637–1643. doi: 10.1016/S0140-6736(20)32332-1
  17. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi: 10.1056/NEJMoa1410489
  18. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–261. doi: 10.1016/j.atherosclerosis.2012.02.016
  19. Smolina MO, Benimetskaya KS, Ragino YuI, et al. PCSK9: new victory and horizons. Ateroscleroz. 2018;14(3):70–77. (In Russ). doi: 10.15372/ATER20180311
  20. Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/NEJMoa1615664
  21. Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc Res. 2019;115(3):26–31. doi: 10.1093/cvr/cvy301
  22. Ezhov MV, Bazhan SS, Ershova AI, et al. Сlinical guidelines for familial hypercholesterolemia. Ateroscleroz. 2019;15(1):58–98. (In Russ).
  23. Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395–1407. doi: 10.1056/NEJMoa1915922
  24. Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203. doi: 10.1016/j.atherosclerosis.2018.06.002
  25. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russian Journal of Cardiology. 2020;25(5):3826. (In Russ). doi: 10.15829/1560-4071-2020-3826
  26. Ference BA, Ray KK, Catapano AL, et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380(11):1033–1042. doi: 10.1056/NEJMoa1806747
  27. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780–1788. doi: 10.1001/jama.2019.16585
  28. Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662. doi: 10.1161/JAHA.118.011662
  29. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–1032. doi: 10.1056/NEJMoa1803917
  30. Arabidze GG. Review based on the materials of the 88th congress of the European atherosclerosis society (EAS) held on October 04–07, 2020 in on-line format. Journal of Atherosclerosis and Dyslipidemias. 2020;4(41):44–46. (In Russ). doi: 10.34687/2219-8202.JAD.2020.04.0006
  31. Bliznyuk SA, Bubnova MG, Ezhov MV. Familial hypercholesterolemia: current status of the problem, treatment, and prevention. Cardiovascular Therapy and Prevention. 2020;19(5):247–252. (In Russ). doi: 10.15829/1728-8800-20202532
  32. Drapkina OM, Ivanova AA. Personalized medicine in non-communicable diseases: latest advances and future prospects. Kardiologiia. 2021;61(11):98–103. (In Russ). doi: 10.18087/cardio.2021.11.n1233
  33. Shakhtshneider EV, Orlov PS, Shcherbakova LV, et al. A panel of genetic markers for analyzing the risk of long-term adverse prognosis of cardiovascular diseases. Ateroscleroz. 2018;14(3):12–19. (In Russ). doi: 10.15372/ATER20180302
  34. Nobel Prize in Physiology or Medicine. Available from: https://www.nobelprize.org/prizes/medicine/2006/summary/. Accessed: 17.02.2023.
  35. Crooke ST, Witztum J, Bennett C, et al. RNA-Targeted Therapeutics. Cell Metab. 2018;27(4):714–739. doi: 10.1016/j.cmet.2018.03.004
  36. Afanasieva OI, Ezhov MV, Pokrovsky SN. Antisense oligonucleotides and therapeutical monoclonal antibodies as a basement for novel biological lipidlowering drugs. Russian Journal of Cardiology. 2018;8:99–109. (In Russ). doi: 10.15829/1560-4071-2018-8-99-109
  37. Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16(9):543–552. doi: 10.1038/nrg3978
  38. Barba AA, Bochicchio S, Dalmoro A, et al. Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications. Pharmaceutics. 2019;11(8):360. doi: 10.3390/pharmaceutics11080360
  39. Khorova A. Oligonucleotide Therapeutics – A New Class of Cholesterol-Lowering Drugs. N Engl J Med. 2017;376(1):4–7. doi: 10.1056/NEJMp1614154
  40. Chubykina UV, Ezhov MV, Saidova MA, et al. Severe aortic valve stenosis with rapidly progressive atherosclerosis in a young woman with homozygous familial hypercholesterolemia: the possibilities of surgical and therapeutic treatment. Russian Cardiology Bulletin. 2021;16(2):65–71. (In Russ). doi: 10.17116/Cardiobulletin20211602165
  41. Cupido AJ, Kastelein JJP. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials. Cardiovasc Res. 2020;116(11):136–139. doi: 10.1093/cvr/cvaa212
  42. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020; 382(16):1520–1530. doi: 10.1056/NEJMoa1913805
  43. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol for the ORION-10 and ORION-11 Investigators. N Engl J Med. 2020;382(16):1507–1519. doi: 10.1056/NEJMoa1912387

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies